Fragile X Syndrome – Fmr1 KO Mouse Model
Accelerate the availability of targeted FXS therapies with the well-characterized and translationally relevant in vivo Fmr1 KO model
Fmr1 KO Key Model Characteristics
Fragile X Syndrome (FXS) is the most prevalent inherited cause of mild-to-severe cause of intellectual disability and the most common monogenic cause of autism spectrum disorder (ASD). FXS is caused by mutations in the fragile X mental retardation protein 1 (FMR1) gene, resulting in the deficiency of the FMRP protein that plays a key role in synaptogenesis, as well as synaptic plasticity and architecture. The Fmr1 KO mouse model replicates many phenotypic features of human FXS, and therefore, represents a highly translationally relevant mouse model to study efficacy of novel disease-modifying treatments for FXS.
InnoSer is committed to helping industry innovators to accelerate the availability of FXS modifying-treatment to patients through our extensive experience in carrying out efficacy studies in the Fmr1 KO mouse model. Accordingly, InnoSer offers preclinical research services focusing on evaluating therapeutic efficacy in the Fmr1 KO mouse model via multiple validated behavioral readouts.
✓ Model is characterized on the C57BL/6J and FVB background.
✓ Altered spontaneous behaviours, cognitive impairment, hyperactivity, altered anxiety levels, and decreases in social interactions.
✓ Changes in Event-Related Potentials (ERP) in electrocorticography (ECoG) typically observed in FXS patients are detectable in Fmr1 KO mice.
✓ Phenotypic similarities observed are confirmed by extensive in-house validation via several protocols using automated home-cage systems (PhenoTyper™) and conventional behavioural tests (portion of results published together with Kramvis et al., 2013).
✓ Fmr1 KO mice show key FXS characteristics at young age (starting at 6 weeks of age), allowing efficacy testing of targeted interventions as early as post-natal day 1.
Take advantage of InnoSer’s expertise, flexibility and collaborative approach for your research. We support our clients in identifying new drugs or applications, characterizing their pharmacological properties, and conducting safety and efficacy testing with state-of-the-art readout capabilities and histopathological analysis.
InnoSer’s neurology expert team possesses relevant experience in working with multiple therapy types ranging from small molecules, peptides, enzymes, oligonucleotides, and gene therapy (viral vectors – e.g.. AAVs).
Your Fragile X Syndrome Research Starts Here.
Access detailed study timelines, essential readouts, and robust validation data for the Fmr1 KO mouse model (on C57BL/6J and FVB backgrounds).
Fmr1 KO Sample Data
Fmr1 KO mice show impaired performance in the discrimination learning that can be detected using CognitionWall™ discrimination learning task
Using the CognitionWall™, we developed a one-night automated test to efficiently identify discrimination learning impairments in mice, without time-consuming handling of mice. The CognitionWall™ is a wall with three entrances in front of a food dispenser. Mice are rewarded with a food reward when they choose to pass through one of the three entrances. The rate at which a mouse gains a relative preference for the rewarded entrance is used as a measure of discrimination learning.
Recent literature indicates that clinical EEG recording in FXS patients shows differences in ERP amplitudes; a phenomenon that we also detect in the Fmr1 KO mouse model of FXS.
Experimental setup for auditory event-related potential (AERP) EEG recording. During an ERP recording session, multiple trials are provided with a 100 msec white noise stimulus (~70 dB), with 4-6 sec inter trial interval. Trials with movement artifacts (deducted from XYZ activity) are excluded, generating a clean average AERP trace for the auditory cortex electrode.
Fmr1 KO Readouts
Paramètres biologiques
EEG analyses and post-mortem analyses:
- Baseline spectral analyses of ECoG data
- Analysis of Auditory event related potentials in ECoG data
- Tissue collection & analysis
Publications phares de notre équipe
- Kramvis, I., Mansvelder, H. D., Loos, M., & Meredith, R. (2013). Hyperactivity, perseveration and increased responding during attentional rule acquisition in the Fragile X mouse model. Frontiers in behavioral neuroscience, 7, 172. https://doi.org/10.3389/fnbeh.2013.00172
Les personnes qui travaillent sur vos recherches
Sofie Carmans, docteure
Chercheur principal en neurologie
Thomas Vogels, docteur ès sciences
Chercheur principal en neurologie
Découvrez d'autres modèles de maladies génétiques rares pertinents
Découvrez les dernières recherches d'InnoSer
![Cognitive profiling in the APP[V717I]xTau[P301S] mouse model](https://www.innoserlaboratories.com/wp-content/uploads/2026/07/Figure-1-MWM.png)
Cognitive profiling in the APP[V717I]xTau[P301S] mouse model
In this month's update, we revisit the APP[V717I]xTau[P301S] model with newly in-house generated Morris Water Maze (MWM) data, reconfirming the spatial memory deficits previously described for this model and reinforcing the translational value of the model.The...
![Neurosciences translationnelles : profilage longitudinal complet des souris femelles et mâles porteurs de la mutation Tau[P301S]](https://www.innoserlaboratories.com/wp-content/uploads/2026/06/Female-TauP301S-mice-show-early-spontaneous-hyperactivity-in-automated-home-cages-PhenoTyperTM-229375_1080x323.png)
Neurosciences translationnelles : profilage longitudinal complet des souris femelles et mâles porteurs de la mutation Tau[P301S]
Dans la lettre d'information de ce mois-ci, nous mettons en avant et approfondissons nos connaissances acquises grâce à l'utilisation du modèle murin Tau[P301S] (décrit à l'origine par Allen et al., 2002), ainsi que son applicabilité dans la recherche préclinique. Les femelles et les mâles...
Panels de biomarqueurs cliniquement pertinents pour des études d'efficacité exhaustives sur des modèles murins de la maladie d'Alzheimer
Les modèles murins validés d'InnoSer pour la maladie d'Alzheimer (MA) intègrent des panels de biomarqueurs pertinents sur le plan translationnel — couvrant les espèces de bêta-amyloïde (Aβ), les isoformes phosphorylées de la protéine Tau, ainsi que le marqueur précoce et sensible de la neurodégénérescence que constituent les neurofilaments légers...
![Modèle murin Tau[P301S] dont la sensibilité au composé a été démontrée, destiné à la validation préclinique du concept](https://www.innoserlaboratories.com/wp-content/uploads/2026/03/Proven-Compound-susceptible-TauP301S-mouse-model-for-preclinical-proof-of-concept--1080x675.png)
Modèle murin Tau[P301S] dont la sensibilité au composé a été démontrée, destiné à la validation préclinique du concept
La souris Tau[P301S] reste l'un des modèles in vivo les plus reconnus pour l'évaluation de traitements ciblant les tauopathies, notamment la maladie d'Alzheimer et la démence frontotemporale (DFT). Présentée lors du congrès AD/PD 2025 à Vienne, cette affiche offre un aperçu complet...
Accréditation AAALAC
InnoSer a obtenu l'accréditation AAALAC, ce qui témoigne de notre engagement en faveur d'une prise en charge et d'une utilisation responsables des animaux. AAALAC International est une organisation à but non lucratif qui promeut le traitement sans cruauté des animaux dans le domaine scientifique par le biais de programmes volontaires d'accréditation et d'évaluation. Notre accréditation est valable trois ans, y compris en 2023. Pour en savoir plus sur le programme d'accréditation AAALAC ici.
Bien-être animal
Les « 3R » ont une incidence sur tous les domaines, depuis les changements politiques et réglementaires jusqu’au développement et à l’adoption de nouvelles technologies et approches. C’est pourquoi Innoser s’engage en permanence à suivre ces processus. Les mesures que nous mettons en œuvre optimisent notre capacité à remplacer, réduire et perfectionner l’utilisation des animaux et facilitent notre engagement envers ces principes dans le cadre de la recherche et du développement de médicaments.
info@innoserlaboratories.com
Liens rapides